Figure 2. Progression-Free Survival in Patients With Metastatic Breast Cancer From Phase 2.

Patients without progression/death were censored at the date of the last tumor assessment. HR estimates and 90% CIs are from a Cox regression model stratified by the number of previous lines of treatment.

HR indicates hazard ratio; T-DM1, trastuzumab emtansine.